Noxopharm CEO , Dr Graham Kelly, and Director of Clinical Development and Medical Affairs, Mr Ian Minns, will present updates on Noxopharm's (ASX:NOX) NOX66 clinical programme and onocology and non-oncology R&D pipelines.
The briefings are open to all interested parties.
Download this document
